Navigation Links
Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients
Date:4/10/2008

Data from 150 lung transplant patients demonstrates potential to improve

management of risk for infection

BOSTON, April 10 /PRNewswire/ -- A prospective analysis of data collected from 170 patients receiving lung transplantation at the University of Pittsburgh Medical Center (UPMC) has suggested that the ImmuKnow(R) assay of cell-mediated immunity (CMI), when combined with microbial analysis of bronchoalveolar (BAL) fluids in immunosuppressed patients, can help to differentiate between patients with fungal colonization and those patients with active fungal infections. These data were presented in an oral session today by Shahid Husain, MD at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in Boston, MA.

"Our hypothesis was that global immunoreactivity, as measured prospectively using the ImmuKnow assay of CMI, would be different for patients with fungal colonization as compared to patients with true fungal infections," said Dr. Husain. "This hypothesis appears to have been borne out by our preliminary results."

"Our study has shown that ImmuKnow values are significantly different for patients with fungal colonization as compared to patients with true fungal infections six months after transplantation," Husain continued.

Data were collected prospectively from 170 lung transplant recipients at UPMC between 2003 and 2006. These patients provided a total of 712 blood samples for analysis, while also being prospectively monitored and classified for episodes of infection according to standardized criteria.

All patients received alemtuzumab induction and tacrolimus suppression to prevent organ rejection. Results of ImmuKnow assays of CMI were included in the analysis if and when they were obtained within 30 days of a documented episode of clinical syndrome (fungal colonization/ fungal disease).

In the initial 6-month period following T-cell depletion (while patients were still receiving prophylaxis), the investigators observed no statistical differences between measures of CMI and clinical condition of the patients. However, beginning six months after transplantation, when prophylaxis was stopped, there were significant differences in CMI between clinically stable patients (188 ng/mL ATP) and those with evident infections documented by microbial analysis of BAL (91 ng/mL ATP; p < 0.001). The median ImmuKnow measure of CMI based on samples from 45 patients diagnosed with fungal colonization (but no clinical infection) was 188 ng/mL ATP, which was not significantly different from the median value of samples from all clinically stable patients. However, this CMI value was significantly higher than the value in the six transplant patients with fungal disease (78 ng/mL ATP; p < 0.01).

"This study expands our understanding of the applicability of the ImmuKnow immune function assay in effective management of lung transplant recipients in the post-transplant setting," stated Dr. Husain. "While we had demonstrated an association between infection and low ImmuKnow values in an earlier study, we now have specific preliminary prospective evidence that will guide us in predicting risk for fungal infection in these immune-suppressed patients over time."

Dr. Husain's presentation was entitled, "Use of an immune monitoring assay to distinguish between fungal colonization and fungal disease in lung transplant recipients." Dr. Husain is currently Assistant Professor of Medicine and Director of Transplant Infectious Diseases in the Division of Infectious Diseases and Multi-Organ Transplantation, Toronto General Hospital- University Health Network, Toronto, Canada.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult immunosuppressed patients by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression.

Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The use of the ImmuKnow assay as described in this study has not been cleared by the FDA. The company may use data from this study or similar studies to support a future FDA marketing application for a similar indication.

ImmuKnow is a product of Cylex(TM), a privately held global life sciences company and the leader in the development and manufacture of research and in vitro diagnostic products intended to assist in the assessment of immune function.

About Cylex(TM) Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow(R) is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the US and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The Company is based in Columbia, MD.


'/>"/>
SOURCE Cylex
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
4. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. D1 Sports Training Facilities Adopt TurfAide(TM) Antimicrobial to New Synthetic Turf Fields from AstroTurf(R)
7. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
9. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
10. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... The latest research Hemophilia Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: What ... are they positioned in the Global Hemophilia market? What ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
(Date:2/24/2017)... N.C. , Feb. 24, 2017 ... exploring ways to increase their self-service capabilities to ... Care Providers (HCPs). New research from ... pharma organizations have developed self-service website portals where ... This is just one of many findings to ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):